JP4781855B2 - Composite powder and makeup cosmetic containing the composite powder - Google Patents
Composite powder and makeup cosmetic containing the composite powder Download PDFInfo
- Publication number
- JP4781855B2 JP4781855B2 JP2006062696A JP2006062696A JP4781855B2 JP 4781855 B2 JP4781855 B2 JP 4781855B2 JP 2006062696 A JP2006062696 A JP 2006062696A JP 2006062696 A JP2006062696 A JP 2006062696A JP 4781855 B2 JP4781855 B2 JP 4781855B2
- Authority
- JP
- Japan
- Prior art keywords
- powder
- composite powder
- tocopherol phosphate
- cosmetics
- phosphate ester
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000843 powder Substances 0.000 title claims description 161
- 239000002131 composite material Substances 0.000 title claims description 67
- 239000002537 cosmetic Substances 0.000 title claims description 59
- -1 α-tocopherol phosphate ester salt Chemical class 0.000 claims description 52
- JUIUXBHZFNHITF-IEOSBIPESA-N [(2r)-2,5,7,8-tetramethyl-2-[(4r,8r)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] dihydrogen phosphate Chemical class OP(=O)(O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C JUIUXBHZFNHITF-IEOSBIPESA-N 0.000 claims description 24
- 239000010445 mica Substances 0.000 claims description 10
- 229910052618 mica group Inorganic materials 0.000 claims description 10
- 239000000454 talc Substances 0.000 claims description 9
- 229910052623 talc Inorganic materials 0.000 claims description 9
- 239000004677 Nylon Substances 0.000 claims description 7
- 239000001913 cellulose Substances 0.000 claims description 7
- 229920002678 cellulose Polymers 0.000 claims description 7
- 229920001778 nylon Polymers 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 7
- 239000005995 Aluminium silicate Substances 0.000 claims description 6
- 235000012211 aluminium silicate Nutrition 0.000 claims description 6
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims description 6
- RJDOZRNNYVAULJ-UHFFFAOYSA-L [O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[F-].[F-].[Mg++].[Mg++].[Mg++].[Al+3].[Si+4].[Si+4].[Si+4].[K+] Chemical compound [O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[F-].[F-].[Mg++].[Mg++].[Mg++].[Al+3].[Si+4].[Si+4].[Si+4].[K+] RJDOZRNNYVAULJ-UHFFFAOYSA-L 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 29
- 238000004519 manufacturing process Methods 0.000 description 27
- 239000000203 mixture Substances 0.000 description 25
- 229920001296 polysiloxane Polymers 0.000 description 19
- 230000000052 comparative effect Effects 0.000 description 18
- 230000005068 transpiration Effects 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- 238000009472 formulation Methods 0.000 description 15
- 238000000034 method Methods 0.000 description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
- 239000003921 oil Substances 0.000 description 10
- 239000002585 base Substances 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 229910052751 metal Inorganic materials 0.000 description 8
- 239000002184 metal Substances 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- 229910052708 sodium Inorganic materials 0.000 description 8
- 230000002776 aggregation Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 6
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 6
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 6
- 239000011732 tocopherol Substances 0.000 description 6
- 238000005054 agglomeration Methods 0.000 description 5
- 230000000536 complexating effect Effects 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 239000003205 fragrance Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 229930003799 tocopherol Natural products 0.000 description 5
- 229960001295 tocopherol Drugs 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 4
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 235000012239 silicon dioxide Nutrition 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000010936 titanium Substances 0.000 description 4
- 229910052719 titanium Inorganic materials 0.000 description 4
- 235000010384 tocopherol Nutrition 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229910052582 BN Inorganic materials 0.000 description 3
- PZNSFCLAULLKQX-UHFFFAOYSA-N Boron nitride Chemical compound N#B PZNSFCLAULLKQX-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000013329 compounding Methods 0.000 description 3
- 239000004205 dimethyl polysiloxane Substances 0.000 description 3
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 3
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 3
- 239000004926 polymethyl methacrylate Substances 0.000 description 3
- 238000010298 pulverizing process Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- 238000004381 surface treatment Methods 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 238000010306 acid treatment Methods 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000013350 formula milk Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 239000004200 microcrystalline wax Substances 0.000 description 2
- 235000019808 microcrystalline wax Nutrition 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000004071 soot Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- XLTMWFMRJZDFFD-UHFFFAOYSA-N 1-[(2-chloro-4-nitrophenyl)diazenyl]naphthalen-2-ol Chemical compound OC1=CC=C2C=CC=CC2=C1N=NC1=CC=C([N+]([O-])=O)C=C1Cl XLTMWFMRJZDFFD-UHFFFAOYSA-N 0.000 description 1
- GNCOVOVCHIHPHP-UHFFFAOYSA-N 2-[[4-[4-[(1-anilino-1,3-dioxobutan-2-yl)diazenyl]-3-chlorophenyl]-2-chlorophenyl]diazenyl]-3-oxo-n-phenylbutanamide Chemical compound C=1C=CC=CC=1NC(=O)C(C(=O)C)N=NC(C(=C1)Cl)=CC=C1C(C=C1Cl)=CC=C1N=NC(C(C)=O)C(=O)NC1=CC=CC=C1 GNCOVOVCHIHPHP-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 235000010919 Copernicia prunifera Nutrition 0.000 description 1
- 244000180278 Copernicia prunifera Species 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 239000004640 Melamine resin Substances 0.000 description 1
- 229920000877 Melamine resin Polymers 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000006087 Silane Coupling Agent Substances 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Natural products C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 1
- WGLPBDUCMAPZCE-UHFFFAOYSA-N Trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000005250 alkyl acrylate group Chemical group 0.000 description 1
- 125000005210 alkyl ammonium group Chemical group 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229940009868 aluminum magnesium silicate Drugs 0.000 description 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000010426 asphalt Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- IRERQBUNZFJFGC-UHFFFAOYSA-L azure blue Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[S-]S[S-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-] IRERQBUNZFJFGC-UHFFFAOYSA-L 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 229910052916 barium silicate Inorganic materials 0.000 description 1
- POJOORKDYOPQLS-UHFFFAOYSA-L barium(2+) 5-chloro-2-[(2-hydroxynaphthalen-1-yl)diazenyl]-4-methylbenzenesulfonate Chemical compound [Ba+2].C1=C(Cl)C(C)=CC(N=NC=2C3=CC=CC=C3C=CC=2O)=C1S([O-])(=O)=O.C1=C(Cl)C(C)=CC(N=NC=2C3=CC=CC=C3C=CC=2O)=C1S([O-])(=O)=O POJOORKDYOPQLS-UHFFFAOYSA-L 0.000 description 1
- HMOQPOVBDRFNIU-UHFFFAOYSA-N barium(2+);dioxido(oxo)silane Chemical compound [Ba+2].[O-][Si]([O-])=O HMOQPOVBDRFNIU-UHFFFAOYSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940073609 bismuth oxychloride Drugs 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000004204 candelilla wax Substances 0.000 description 1
- 229940073532 candelilla wax Drugs 0.000 description 1
- 235000013868 candelilla wax Nutrition 0.000 description 1
- 239000006229 carbon black Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229910000423 chromium oxide Inorganic materials 0.000 description 1
- VQWFNAGFNGABOH-UHFFFAOYSA-K chromium(iii) hydroxide Chemical compound [OH-].[OH-].[OH-].[Cr+3] VQWFNAGFNGABOH-UHFFFAOYSA-K 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- LQJVOKWHGUAUHK-UHFFFAOYSA-L disodium 5-amino-4-hydroxy-3-phenyldiazenylnaphthalene-2,7-disulfonate Chemical compound [Na+].[Na+].OC1=C2C(N)=CC(S([O-])(=O)=O)=CC2=CC(S([O-])(=O)=O)=C1N=NC1=CC=CC=C1 LQJVOKWHGUAUHK-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003822 epoxy resin Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- SXQCTESRRZBPHJ-UHFFFAOYSA-M lissamine rhodamine Chemical compound [Na+].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S([O-])(=O)=O)C=C1S([O-])(=O)=O SXQCTESRRZBPHJ-UHFFFAOYSA-M 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- BWOROQSFKKODDR-UHFFFAOYSA-N oxobismuth;hydrochloride Chemical compound Cl.[Bi]=O BWOROQSFKKODDR-UHFFFAOYSA-N 0.000 description 1
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 229910052628 phlogopite Inorganic materials 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 238000009832 plasma treatment Methods 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920005668 polycarbonate resin Polymers 0.000 description 1
- 239000004431 polycarbonate resin Substances 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 238000009725 powder blending Methods 0.000 description 1
- 235000020610 powder formula Nutrition 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 229920002050 silicone resin Polymers 0.000 description 1
- 229910021647 smectite Inorganic materials 0.000 description 1
- VVNRQZDDMYBBJY-UHFFFAOYSA-M sodium 1-[(1-sulfonaphthalen-2-yl)diazenyl]naphthalen-2-olate Chemical compound [Na+].C1=CC=CC2=C(S([O-])(=O)=O)C(N=NC3=C4C=CC=CC4=CC=C3O)=CC=C21 VVNRQZDDMYBBJY-UHFFFAOYSA-M 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 230000036572 transepidermal water loss Effects 0.000 description 1
- QPQANCNBWQXGTQ-UHFFFAOYSA-N trihydroxy(trimethylsilylperoxy)silane Chemical compound C[Si](C)(C)OO[Si](O)(O)O QPQANCNBWQXGTQ-UHFFFAOYSA-N 0.000 description 1
- UJMBCXLDXJUMFB-UHFFFAOYSA-K trisodium;5-oxo-1-(4-sulfonatophenyl)-4-[(4-sulfonatophenyl)diazenyl]-4h-pyrazole-3-carboxylate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-UHFFFAOYSA-K 0.000 description 1
- 235000013799 ultramarine blue Nutrition 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 229910001928 zirconium oxide Inorganic materials 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Cosmetics (AREA)
Description
本発明は、核粉体とα−トコフェロールリン酸エステル塩からなる複合粉体及び当該複合粉体を含有するメイクアップ化粧料に関する。 The present invention relates to a composite powder comprising a core powder and an α-tocopherol phosphate ester salt and a makeup cosmetic containing the composite powder.
ビタミンEとして知られるトコフェロール類は皮膚に浸透しやすく、過酸化脂質生成防止、細胞膜の強化、血行促進等の効果を持ち、化粧料や医薬部外品に使用されている反面、酸化されやすく不安定であり、水に対する溶解性も不十分である。そこで、トコフェロールをリン酸エステル化することにより、その安定性および水溶性を改善したトコフェロールリン酸エステル塩が開発され、これを含有する化粧料が提案されている(特許文献1)。 Tocopherols, known as vitamin E, easily penetrate into the skin and have effects of preventing lipid peroxide formation, strengthening cell membranes, promoting blood circulation, etc. While being used in cosmetics and quasi-drugs, they are easily oxidized and not. It is stable and has poor solubility in water. Then, the tocopherol phosphate salt which improved the stability and water solubility was developed by phosphoric esterifying tocopherol, and the cosmetics containing this have been proposed (patent document 1).
これらのトコフェロールリン酸エステル塩の中でもα体であるα−トコフェロールリン酸エステル塩は、保湿作用、抗酸化作用等の生理作用効果が高い粉末であり、この水溶液を肌に塗布すると、しっとりとした感触や特有の粘性を感じとることができる。しかしながら、α−トコフェロールリン酸エステル塩の粉末原体は、吸湿・潮解性が高いため、湿気を吸って凝集を起こし固まりになりやすい性質があり、一度、固まりが生じると、容器や器具に強固に固着するため、再度解砕することは難しくなる。 Among these tocopherol phosphate salts, α-tocopherol phosphate ester salt which is an α form is a powder having high physiological effects such as moisturizing action and antioxidant action, and when this aqueous solution is applied to the skin, it is moist. You can feel the feel and peculiar viscosity. However, the powdery base of α-tocopherol phosphate ester salt is highly hygroscopic and deliquescent, and therefore has the property of absorbing moisture and causing agglomeration and becoming agglomerated. It becomes difficult to crush again because it adheres to the surface.
α−トコフェロールリン酸エステル塩の生理作用やその使用感を期待して、メイクアップ化粧料へ添加を検討したが、メイクアップ化粧料の多くは水分量の少ない粉末化粧料の剤形をとるため、スキンケア化粧品のようにα−トコフェロールリン酸エステル塩を水に溶解して配合することは難しい。そこで、α−トコフェロールリン酸エステル塩を粉末の状態でメイクアップ化粧料へ添加を試みたが、製造途中の凝集の発生により他の成分と均一に分散させることが困難であるばかりか、製造後も徐々に吸湿が進行して新たな凝集物の発生により製品としての安定性に問題があった。また、使用感についても、この固まりがざらつきと感じられ、肌上へのベースの付着性が低くなり、化粧のりが悪く、化粧崩れを起こしやすくなるという欠点があった。特に、固形粉末化粧料の場合、ベース表面に凝集物が生じて、パフ等の化粧用具へのベースのとれ量が少なくなるというケーキング現象が発生し、使用性の問題もあった。 In anticipation of the physiological action of α-tocopherol phosphate ester salt and its feeling of use, addition to makeup cosmetics was studied, but many makeup cosmetics take the form of powder cosmetics with low moisture content. It is difficult to dissolve α-tocopherol phosphate ester salt in water as in skin care cosmetics. Therefore, we tried to add α-tocopherol phosphate salt to the makeup cosmetics in the form of powder, but it was difficult to disperse uniformly with other ingredients due to the occurrence of aggregation during the production. However, there was a problem in stability as a product due to the progress of moisture absorption and generation of new aggregates. Further, the feeling of use also has the disadvantage that the clumps are perceived as rough, the adhesion of the base to the skin is low, the makeup is poor, and the makeup is liable to break down. In particular, in the case of a solid powder cosmetic, agglomerates are formed on the surface of the base, causing a caking phenomenon in which the amount of the base to be applied to a cosmetic tool such as a puff is reduced, and there is a problem in usability.
一方で、今日のようにメイクアップ化粧料でもスキンケア効果が求められている現状を踏まえると、α−トコフェロールリン酸エステル塩のようなスキンケア効果が高い素材を安定化した形で、さらには、α−トコフェロールリン酸エステル塩が有するしっとりとした感触や、その粘着特性による肌への付着性を活かした剤形を開発することは重要である。 On the other hand, in light of the current situation where skin care effects are required even in makeup cosmetics like today, in the form of stabilized skin care effects such as α-tocopherol phosphate ester salts, -It is important to develop a dosage form that takes advantage of the moist feel of the tocopherol phosphate ester salt and the adhesion to the skin due to its adhesive properties.
従って、本発明の目的は、吸湿等により凝集して固まりやすいα−トコフェロールリン酸エステル塩を、化粧料中に均一に含有させて、化粧用具へのとれや使用性が滑らかで、しっとりとした使用感と肌への付着性が優れた粉末化粧料や油性化粧料等のメイクアップ化粧料を提供することにある。 Accordingly, an object of the present invention is to uniformly contain α-tocopherol phosphate ester salt that easily aggregates and hardens due to moisture absorption or the like in the cosmetic, and is smooth and moist to use in cosmetics. An object of the present invention is to provide makeup cosmetics such as powder cosmetics and oil-based cosmetics that have excellent usability and adhesion to the skin.
すなわち、本発明は、核粉体とα−トコフェロールリン酸エステル塩からなる複合粉体が凝集して固まることなく、メイクアップ化粧料の他の成分と均一に分散することができ、また、当該複合粉体を固形粉末化粧料、粉末化粧料、油性化粧料等のメイクアップ化粧料に含有することにより、化粧用具へのとれや使用性が滑らかで、しっとりとした使用感と肌への付着性が優れるという特性を見出した。なお、本発明でいう複合粉体とは基材となる核粉体に異種成分が付着、吸着、結合又は含浸等して一体化して粉体を形成している物質を示す。 That is, the present invention can uniformly disperse the other components of the makeup cosmetic without agglomerating and solidifying the composite powder comprising the core powder and the α-tocopherol phosphate ester salt, By containing the composite powder in makeup cosmetics such as solid powder cosmetics, powder cosmetics, and oily cosmetics, the cosmetics are smooth and easy to use and have a moist feel and adhesion to the skin. The characteristic that the property is excellent was found. The composite powder as used in the present invention refers to a substance that forms a powder by integrating, adhering, adsorbing, bonding or impregnating different kinds of components to the core powder as a base material.
本発明の核粉体とα−トコフェロールリン酸エステル塩からなる複合粉体は、凝集して固まることなく、メイクアップ化粧料の他の成分と均一に分散することができ、当該複合粉体を含有するメイクアップ化粧料は、化粧用具へのとれや使用性が滑らかで、しっとりとした使用感と肌への付着性が優れるという利点がある。 The composite powder composed of the core powder of the present invention and the α-tocopherol phosphate ester salt can be uniformly dispersed with other components of the makeup cosmetic without agglomerating and solidifying. The makeup cosmetics to be contained have the advantage that they are smooth and easy to use in cosmetics and have a moist feeling of use and excellent adhesion to the skin.
本発明で用いられるα−トコフェロールリン酸エステル塩は化学式1で表される化合物である。 The α-tocopherol phosphate ester salt used in the present invention is a compound represented by Chemical Formula 1.
(化学式1)
R1、R2はそれぞれ水素、金属、アンモニウム、アルキルアンモニウムから選ばれ、同一でも異種でも構わない。
(Chemical formula 1)
R 1 and R 2 are each selected from hydrogen, metal, ammonium and alkylammonium, and may be the same or different.
本発明で基材となる核粉体としては、通常化粧料に用いられているものであれば全て適用できる。例えば、無機顔料では、タルク、マイカ、合成マイカ、カオリン、セリサイト、ベントナイト、スメクタイト、雲母チタン、オキシ塩化ビスマス、ケイ酸、無水ケイ酸、ケイ酸アルミニウムマグネシウム、アルミナ、酸化チタン、微粒子酸化チタン、酸化亜鉛、酸化ジルコニウム、酸化マグネシウム、硫酸バリウム、硫酸マグネシウム、炭酸カルシウム、炭酸マグネシウム、ケイ酸アルミニウム、ケイ酸マグネシウム、ケイ酸カルシウム、ケイ酸バリウム、ヒドロキシアパタイト、窒化ホウ素、金属石鹸、ベンガラ、黄酸化鉄、黒酸化鉄、酸化クロム、水酸化クロム、カーボンブラック、群青、紺青等が挙げられる。また、有機粉体では、ナイロン、ポリメチルメタクリレート、ポリエチレン、ポリスチレン、セルロース、アセチル化セルロース、ポリウレタン、ジビニルベンゼン・スチレン共重合体、シリコーン樹脂、エポキシ樹脂、メラミン樹脂、ポリカーボネート樹脂、ビニル樹脂、シルクパウダー等が挙げられる。さらにタール系色素では、赤色104号、赤色106号、赤色201号、赤色202号、赤色204号、赤色205号、赤色206号、赤色226号、赤色227号、赤色228号、黄色4号、黄色5号、黄色202号、黄色203号、黄色205号、黄色401号、青色1号、緑色3号等が挙げられる。また、2種以上の核粉体およびこれらの複合体を用いても構わず、核粉体の形状、粒径に関しても、特に限定しない。 As the core powder used as the base material in the present invention, any material that is usually used in cosmetics can be applied. For example, for inorganic pigments, talc, mica, synthetic mica, kaolin, sericite, bentonite, smectite, mica titanium, bismuth oxychloride, silicic acid, silicic anhydride, aluminum magnesium silicate, alumina, titanium oxide, fine particle titanium oxide, Zinc oxide, zirconium oxide, magnesium oxide, barium sulfate, magnesium sulfate, calcium carbonate, magnesium carbonate, aluminum silicate, magnesium silicate, calcium silicate, barium silicate, hydroxyapatite, boron nitride, metal soap, bengara, yellow oxide Examples thereof include iron, black iron oxide, chromium oxide, chromium hydroxide, carbon black, ultramarine blue and bitumen. For organic powders, nylon, polymethyl methacrylate, polyethylene, polystyrene, cellulose, acetylated cellulose, polyurethane, divinylbenzene / styrene copolymer, silicone resin, epoxy resin, melamine resin, polycarbonate resin, vinyl resin, silk powder Etc. Further, in the tar-based pigments, red No. 104, red No. 106, red No. 201, red No. 202, red No. 204, red No. 205, red No. 206, red No. 226, red No. 227, red No. 228, yellow No. 4, Yellow No. 5, Yellow No. 202, Yellow No. 203, Yellow No. 205, Yellow No. 401, Blue No. 1, Green No. 3, and the like can be mentioned. Two or more kinds of core powders and composites thereof may be used, and the shape and particle size of the core powder are not particularly limited.
本発明の複合粉体は、α−トコフェロールリン酸エステル塩に由来する付着性としっとり感を有し、化粧料に配合した場合、化粧用具へのとれや使用性が滑らかになる。特に核粉体が、扁平性の高い、いわゆる板状粉体に分類されているタルク、マイカ、合成マイカ、カオリン、セリサイトや、有機粉体の球状ナイロンや球状セルロースである場合、核粉体本来の伸びの滑らかさに加え、付着性、しっとり感が付加され使用感が向上するため、本発明の複合化による効果が発揮される。 The composite powder of the present invention has a sticky and moist feeling derived from α-tocopherol phosphate ester salt, and when blended in a cosmetic, smoothness and usability to a cosmetic tool are smoothed. In particular, when the core powder is talc, mica, synthetic mica, kaolin, sericite, organic powder spherical nylon or spherical cellulose, which is classified as so-called plate powder with high flatness, the core powder In addition to the smoothness of the original elongation, adhesion and moist feeling are added to improve the feeling of use, so that the effect of the combination of the present invention is exhibited.
核粉体は、公知の方法により事前に表面処理されていてもいなくても構わない。また、核粉体とα−トコフェロールリン酸エステル塩を複合化した後に表面処理してもよく、さらに核粉体とα−トコフェロールリン酸エステル塩の複合化と同時に表面処理してもよい。表面処理の方法としては例えば、油剤処理、金属石鹸処理、無機化合物処理、アミノ酸処理、シリコーン処理、フッ素化合物処理、ペンダント処理、シランカップリング剤処理、チタンカップリング剤処理、N−アシル化リジン処理、ポリアクリル酸処理、プラズマ処理、メカノケミカル処理などが挙げられる。また、これらのα−トコフェロールリン酸エステル塩は必要に応じて1種又は2種以上用いることができる。 The core powder may or may not be surface-treated in advance by a known method. Further, the surface treatment may be performed after the core powder and the α-tocopherol phosphate salt are combined, and the surface treatment may be performed simultaneously with the combination of the core powder and the α-tocopherol phosphate salt. Examples of surface treatment methods include oil treatment, metal soap treatment, inorganic compound treatment, amino acid treatment, silicone treatment, fluorine compound treatment, pendant treatment, silane coupling agent treatment, titanium coupling agent treatment, and N-acylated lysine treatment. , Polyacrylic acid treatment, plasma treatment, mechanochemical treatment and the like. Moreover, these alpha-tocopherol phosphate ester salts can be used 1 type, or 2 or more types as needed.
本発明の複合粉体を製造する手法としては、液相法、気相法、メカノケミカル法等が挙げられる。α−トコフェロールリン酸エステル塩は予め水や溶剤に溶解して核粉体に添加してよく、溶解性を調整するために、必要に応じて酸またはアルカリを添加してもよい。酸としては、塩酸、硝酸、硫酸、酢酸等が、アルカリとしては、水酸化ナトリウム、水酸化カリウム、アンモニア、ピリジン、アミン、炭酸ナトリウム等を用いることができる。この時、予め核粉体を水や溶剤に分散させておいてもよい。反応装置はホモミキサー、ディスパーミル、ヘンシェルミキサー、ブレンダー、リボンミキサー、プラネタリー、バキュームニーダー、ロッキングミキサー、ロールミル、ビーズミル、ボールミル、振動ミル、ジェットミル、スーパーミキサー、V型混合機、オートクレーブ、高圧分散機等を使用して複合化することができる。 Examples of the method for producing the composite powder of the present invention include a liquid phase method, a gas phase method, and a mechanochemical method. The α-tocopherol phosphate ester salt may be dissolved in water or a solvent in advance and added to the core powder, and an acid or an alkali may be added as necessary to adjust the solubility. As the acid, hydrochloric acid, nitric acid, sulfuric acid, acetic acid and the like can be used, and as the alkali, sodium hydroxide, potassium hydroxide, ammonia, pyridine, amine, sodium carbonate and the like can be used. At this time, the core powder may be previously dispersed in water or a solvent. Reactors are homomixer, disper mill, Henschel mixer, blender, ribbon mixer, planetary, vacuum kneader, rocking mixer, roll mill, bead mill, ball mill, vibration mill, jet mill, super mixer, V-type mixer, autoclave, high pressure dispersion It can be combined using a machine or the like.
具体的に液相法による複合粉体の製造方法の例としては、α−トコフェロールリン酸エステル塩を水に溶解し、基材の核粉体を添加して撹拌した後、2価の金属塩、3価の金属塩、酸又はアルカリ等を添加し、α−トコフェロールリン酸エステル塩を核粉体の表面に析出させることにより複合化する方法が挙げられる。また、α−トコフェロールリン酸エステル塩を溶解せず、粉末のまま添加する場合は、複合化する前に凝集することを防ぐため、湿度の低い雰囲気下で行うか、ジェットミルなど強力な粉砕能力をもつ撹拌機を用いるのが好ましい。また、複合化した後に、ろ過、減圧操作、加温、フリーズドライ法等により、水分や溶剤を取り除いて乾燥させても良い。さらに、スプレードライ法、流動造粒法等も挙げられるが、いかなる方法であれ、α−トコフェロールリン酸エステル塩が核粉体に付着、吸着、結合又は含浸等して一体化して複合粉体を形成していれば構わない。 Specifically, as an example of a method for producing a composite powder by a liquid phase method, an α-tocopherol phosphate ester salt is dissolved in water, a base core powder is added and stirred, and then a divalent metal salt A method of adding a trivalent metal salt, an acid, an alkali, or the like and depositing an α-tocopherol phosphate ester salt on the surface of the core powder is mentioned. If the α-tocopherol phosphate ester salt is not dissolved and is added as a powder, it should be used in a low humidity atmosphere to prevent agglomeration before complexing, or a powerful crushing ability such as a jet mill. It is preferable to use a stirrer having Moreover, after compounding, moisture and solvent may be removed and dried by filtration, decompression operation, heating, freeze drying method, or the like. Further, spray drying method, fluidized granulation method and the like can be mentioned, but in any method, α-tocopherol phosphate ester salt is attached to the core powder, adsorbed, bonded or impregnated to form a composite powder. It does not matter if it is formed.
本発明の複合粉体において、α−トコフェロールリン酸エステル塩に由来する付着性、しっとり感を考慮すると、複合粉体に含有されるα−トコフェロールリン酸エステル塩の量は、0.5〜15重量%が好ましい。さらに適度な撥水性や滑らかさの使用感を考慮すると、2〜10重量%がより好ましい。 In the composite powder of the present invention, in consideration of adhesion and moist feeling derived from α-tocopherol phosphate ester salt, the amount of α-tocopherol phosphate ester salt contained in the composite powder is 0.5-15. % By weight is preferred. Furthermore, when considering a moderate feeling of water repellency and smoothness, 2 to 10% by weight is more preferable.
本発明のα−トコフェロールリン酸エステル塩の複合粉体を含有する化粧料において、化粧料全量中にα−トコフェロールリン酸エステル塩として含有される量は0.01〜5重量%である。その理由として、0.01重量%未満では本発明の効果である肌への付着性が十分でなく、0.01重量%以上から肌への付着性が優れ、化粧用具への十分なとれが得られる。5重量%を越えても、効果の増強は望めない。また、α−トコフェロールリン酸エステル塩を複合化することなく、単独で固形粉末化粧料へ配合した場合、0.01重量%以上から、湿度の高い過酷な条件下ではベース表面の凝集物やケーキングが認められるので、本発明の複合化による効果として、化粧料全量中のα−トコフェロールリン酸エステル塩の含有量は0.01重量%以上が顕著である。 In the cosmetic containing the composite powder of the α-tocopherol phosphate salt of the present invention, the amount contained as the α-tocopherol phosphate ester salt in the total amount of the cosmetic is 0.01 to 5% by weight. The reason for this is that if it is less than 0.01% by weight, the adhesion to the skin, which is the effect of the present invention, is not sufficient, and if it is 0.01% by weight or more, the adhesion to the skin is excellent, and it is sufficient for cosmetics. can get. Even if it exceeds 5% by weight, the enhancement of the effect cannot be expected. In addition, when compounded into a solid powder cosmetic alone without complexing α-tocopherol phosphate ester salt, the base surface agglomerates and caking under severe conditions with high humidity from 0.01% by weight or more. Therefore, as an effect of the complexing of the present invention, the content of the α-tocopherol phosphate ester salt in the total amount of the cosmetic is not less than 0.01% by weight.
さらに、粉末の状態で塗布する化粧料である固形粉末化粧料のパウダーファンデーションが塗膜によって水分の蒸散をいかに抑えるかという観点で、複合粉体化したα−トコフェロールリン酸エステル塩を配合した場合の保湿効果を評価すると、α−トコフェロールリン酸エステル塩を2重量%以上含む複合粉体を、固形粉末化粧料全量中に1重量%以上含有させれば、水分の蒸散を抑制できる。 Furthermore, in the case of blending α-tocopherol phosphate ester salt made into composite powder from the viewpoint of how the powder foundation of solid powder cosmetics that are cosmetics to be applied in a powder state suppresses transpiration of moisture by the coating film If the composite powder containing 2% by weight or more of α-tocopherol phosphate ester salt is contained in 1% by weight or more in the total amount of the solid powder cosmetic, transpiration of water can be suppressed.
本発明のα−トコフェロールリン酸エステル塩の複合粉体は、化粧料、医薬部外品、医薬品を問わず利用できるが、特に、当該複合粉体を、粉体のまま配合する利用方法を考慮すれば、メイクアップ化粧料、さらには、剤形が固形粉末化粧料、粉末化粧料、油性化粧料、複合粉体を乳化の連続相である油相中に分散させて乳化する油中水型乳化化粧料の形態をとるメイクアップ化粧料への利用に適する。 The composite powder of α-tocopherol phosphate ester salt of the present invention can be used regardless of cosmetics, quasi-drugs, and pharmaceuticals. In particular, a method of using the composite powder as a powder is considered. Then, makeup cosmetics, and further, the dosage form is solid powder cosmetics, powder cosmetics, oily cosmetics, water-in-oil type that emulsifies by dispersing the composite powder in the oil phase which is the continuous phase of emulsification Suitable for use in makeup cosmetics in the form of emulsified cosmetics.
本発明の化粧料には、本発明である核粉体とα−トコフェロールリン酸エステル塩からなる複合粉体の他に、必要に応じて本発明の効果を損なわない範囲で、通常の化粧料、医薬部外品、医薬品に配合される成分である水、油脂、ロウ類、炭化水素、脂肪酸、アルコール、アルキルグリセリルエーテル、エステル、シリコーン油、フッ素油、多価アルコール、糖類、高分子、界面活性剤、保湿剤、紫外線吸収剤、キレート剤、pH調整剤、酸化防止剤、金属イオン封鎖剤、殺菌・防腐剤、染料、香料、色素、可塑剤、有機溶媒、薬剤、動植物抽出物、体質粉体、有機色材、無機色材、パール顔料、表面処理粉体、ゲル化剤、アミノ酸、ペプチド、ビタミン及び本発明の構成成分以外の複合粉体等を適宜配合することができるが、特にこれらに限定されるものではない。 In addition to the composite powder comprising the core powder and α-tocopherol phosphate ester salt of the present invention, the cosmetic composition of the present invention is an ordinary cosmetic composition as long as the effects of the present invention are not impaired as required. , Quasi-drugs, water, fats and oils, waxes, hydrocarbons, fatty acids, alcohols, alkyl glyceryl ethers, esters, silicone oils, fluorine oils, polyhydric alcohols, sugars, polymers, interfaces Activators, moisturizers, UV absorbers, chelating agents, pH adjusters, antioxidants, sequestering agents, bactericides / preservatives, dyes, fragrances, pigments, plasticizers, organic solvents, drugs, animal and plant extracts, constitutions Powders, organic colorants, inorganic colorants, pearl pigments, surface-treated powders, gelling agents, amino acids, peptides, vitamins, and composite powders other than the constituents of the present invention can be appropriately blended. To these Not intended to be constant.
次に実施例を挙げ、本発明を更に詳細に説明するが、本発明はこれに限定されるものではない。 EXAMPLES Next, although an Example is given and this invention is demonstrated still in detail, this invention is not limited to this.
水500gにdl−α−トコフェロールリン酸エステルナトリウム塩10gを溶解し、セリサイト(三信鉱工社製、商品名セリサイトFSE)90gを加えて撹拌した。これに、塩酸を徐々に加えてpH2の酸性とし、さらに1時間撹拌した。その後、水酸化カルシウム水溶液を加えて中和した後、ろ過、水洗し、減圧乾燥して、複合粉体約98gを得た。 10 g of dl-α-tocopherol phosphate sodium salt was dissolved in 500 g of water, and 90 g of sericite (trade name sericite FSE, manufactured by Sanshin Mining Co., Ltd.) was added and stirred. To this, hydrochloric acid was gradually added to make it acidic at pH 2 and further stirred for 1 hour. Then, after adding and neutralizing calcium hydroxide aqueous solution, it filtered, washed with water, and dried under reduced pressure, and obtained about 98g of composite powders.
水500gにd−α−トコフェロールリン酸エステルナトリウム塩10gを溶解し、セルロース(チッソ社製、商品名セルフローC−25)90gを加えて撹拌した。これに、塩化アルミニウム20%水溶液15gを加えた後、ろ過、水洗し、減圧乾燥して、複合粉体約98gを得た。 10 g of d-α-tocopherol phosphate sodium salt was dissolved in 500 g of water, and 90 g of cellulose (trade name Cellflow C-25, manufactured by Chisso Corporation) was added and stirred. To this was added 15 g of an aluminum chloride 20% aqueous solution, followed by filtration, washing with water, and drying under reduced pressure to obtain about 98 g of a composite powder.
水500gにdl−α−トコフェロールリン酸エステルニナトリウム塩10gを溶解し、無水ケイ酸(触媒化成社製、商品名絲粒子シリカP−1500)90gを加えて撹拌した。これを減圧乾燥した後、粉砕して、複合粉体約98gを得た。 10 g of dl-α-tocopherol phosphate disodium salt was dissolved in 500 g of water, and 90 g of anhydrous silicic acid (manufactured by Catalyst Kasei Co., Ltd., trade name: Soot Particle Silica P-1500) was added and stirred. This was dried under reduced pressure and then pulverized to obtain about 98 g of composite powder.
d−α−トコフェロールリン酸エステルカリウム塩100gと、ポリメチルメタクリレート(松本油脂製薬社製、商品名マイクロスフェアーM−503)900gをジェットミルに加えて、混合し、複合粉体約900gを得た。 100 g of d-α-tocopherol phosphate potassium salt and 900 g of polymethyl methacrylate (manufactured by Matsumoto Yushi Seiyaku Co., Ltd., trade name: Microsphere M-503) are added to a jet mill and mixed to obtain about 900 g of a composite powder. It was.
比較例として、各α−トコフェロールリン酸エステル塩の単体を用意した。 As a comparative example, a simple substance of each α-tocopherol phosphate ester salt was prepared.
[比較例1]
dl−α−トコフェロールリン酸エステルナトリウム塩
[Comparative Example 1]
dl-α-tocopherol phosphate sodium salt
[比較例2]
d−α−トコフェロールリン酸エステルナトリウム塩
[Comparative Example 2]
d-α-Tocopherol phosphate sodium salt
[比較例3]
dl−α−トコフェロールリン酸エステルニナトリウム塩
[Comparative Example 3]
dl-α-tocopherol phosphate disodium salt
[比較例4]
d−α−トコフェロールリン酸エステルカリウム塩
[Comparative Example 4]
d-α-Tocopherol phosphate potassium salt
実施例1〜4及び比較例1〜4について、吸湿による固まりの生成を調べるため、下記の試験を行った。
固着凝集試験:試料1gを薬包紙にとり、10cm×10cm四方にヘラで均一に広げる。すぐに、これを温度35℃、湿度75%の恒温恒湿機に6時間静置する。次に薬包紙を裏返し軽く指で叩いて薬包紙に残る試料の有無及び試料の状態を下記基準で確認した。
○:薬包紙に試料が残らず、粉末の状態を保ったまま、固まりもない
△:薬包紙に試料は残らないが、粉末のほかに一部固まりがある
×:薬包紙に試料のほとんどが固まって付着する
About Examples 1-4 and Comparative Examples 1-4, in order to investigate the production | generation of the lump by moisture absorption, the following test was done.
Fixing and agglomeration test: Take 1 g of sample on a medicine wrapping paper and spread it evenly with a spatula on 10 cm x 10 cm square. Immediately, this is left still for 6 hours in a constant temperature and humidity machine with a temperature of 35 ° C. and a humidity of 75%. Next, the medicine wrapping paper was turned over and lightly struck with a finger, and the presence or absence of the sample remaining on the medicine wrapping paper and the state of the sample were confirmed according to the following criteria.
○: No sample remains on the powder wrapping paper and remains in a powder state and does not clump. △: No sample remains on the paper wrapping paper, but there is some solidity in addition to the powder. Do
実施例1〜4及び比較例1〜4について、試験を行った結果を表1に示す。 Table 1 shows the results of tests performed on Examples 1 to 4 and Comparative Examples 1 to 4.
表1の結果から、α−トコフェロールリン酸エステル塩は単独のままでは、吸湿により薬包紙に固着してしまうのに対し、核粉体と複合化した本発明の複合粉体は、いずれも固まりを生じず、粉末の状態を保つことがわかる。 From the results shown in Table 1, the α-tocopherol phosphate ester salt alone is fixed to the medicine-wrapping paper by moisture absorption, whereas the composite powder of the present invention combined with the core powder is all solidified. It does not occur, and it can be seen that the powder state is maintained.
次に実施例5として核粉体種による複合粉体の使用感の違いを調べるため、タルク(浅田製粉社製、商品名タルクJA−68R)、マイカ(山口雲母工業所社製、商品名雲母粉Y−2300)、カオリン(エンゲルハード社製、商品名カオリンASP170)、セリサイト(三信鉱工社製、商品名セリサイトFSE)、球状ナイロン(東レ社製、商品名ナイロン粉末SP−500)、球状セルロース(チッソ社製、商品名セルフローC−25)、合成マイカ(トピー工業社製、商品名PDM−20L)、無水ケイ酸(富士シリシア社製、商品名サイリシア350)、球状無水ケイ酸(触媒化成社製、商品名絲粒子シリカP−1500)、酸化チタン(石原産業社製、商品名タイペークCR−50)、ポリメチルメタクリレート(松本油脂製薬社製、商品名マイクロスフェアーM−503)、窒化ホウ素(東レ社製、商品名トレセラムT-BN-LB)から選ばれる核粉体とd−α−トコフェロールリン酸エステルナトリウム塩からなる、表2に示す複合粉体1〜12を調製した。製法は実施例2の製法に準じた。 Next, in order to investigate the difference in the feeling of use of the composite powder depending on the nuclear powder type as Example 5, talc (manufactured by Asada Flour Milling Co., Ltd., trade name talc JA-68R), mica (manufactured by Yamaguchi Mica Industry Co., Ltd., trade name mica) Powder Y-2300), kaolin (trade name Kaolin ASP170, manufactured by Engelhard), sericite (trade name, Sericite FSE, manufactured by Sanshin Mining Co., Ltd.), spherical nylon (trade name, nylon powder SP-500, manufactured by Toray Industries, Inc.) , Spherical cellulose (trade name Cellflow C-25, manufactured by Chisso Corporation), synthetic mica (trade name: PDM-20L, manufactured by Topy Industries, Ltd.), silicic anhydride (trade name: Silicia 350, manufactured by Fuji Silysia Ltd.), spherical silicic acid anhydride (Catalyst Kasei Co., Ltd., trade name: Soot Particle Silica P-1500), Titanium Oxide (Ishihara Sangyo Co., Ltd., trade name: Taipei CR-50), Polymethylmethacrylate (Matsumoto Yushi Seiyaku) Manufactured by trade name Microsphere M-503), boron nitride (trade name: TRESBN T-BN-LB, manufactured by Toray Industries, Inc.) and d-α-tocopherol phosphate sodium salt, Table 2 Composite powders 1 to 12 shown in Table 1 were prepared. The production method conformed to the production method of Example 2.
実施例5の複合粉体1〜12について、d−α−トコフェロールリン酸エステルナトリウム塩との複合化前の核粉体と、複合化された後の複合粉体との使用感の差を表2に記載の項目について評価した。評価基準としては、複合化前と比較して、使用感が顕著に向上は◎、向上が○、大差なしが△、使用感低下が×とした。 About the composite powders 1-12 of Example 5, the difference in feeling of use between the core powder before complexing with d-α-tocopherol phosphate sodium salt and the composite powder after complexing is shown. The items described in 2 were evaluated. As evaluation criteria, the feeling of use was markedly improved as compared with that before compounding, ◎, the improvement was ◯, no difference was Δ, and the feeling of use was x.
従って、表2の結果から、本発明の複合粉体1〜7においては、のびの滑らかさ、付着性、しっとり感を損なうことなく、複合化により使用感の何れかが顕著に向上している。従って、タルク、マイカ、カオリン、セリサイト、球状ナイロン、球状セルロース、合成マイカの粉体は、α−トコフェロールリン酸エステル塩の吸湿等による固着、凝集防止効果だけでなく、α−トコフェロールリン酸エステル塩と複合化することにより、粉体本来の伸びの滑らかさを活かしながら、又は向上させ、付着性、しっとり感が向上することがわかる。 Therefore, from the results of Table 2, in the composite powders 1 to 7 of the present invention, any of the feelings of use is remarkably improved by the composite without impairing the smoothness, adhesion, and moist feeling of spreading. . Therefore, the powders of talc, mica, kaolin, sericite, spherical nylon, spherical cellulose, and synthetic mica are not only fixed by α-tocopherol phosphate salt due to moisture absorption and the effect of preventing aggregation, but also α-tocopherol phosphate ester. It can be seen that the compounding with the salt improves or improves the adhesion and moist feeling while utilizing or improving the smoothness of the original elongation of the powder.
次に複合粉体中のα−トコフェロールリン酸エステル塩の適切な含有量を決めるため、実施例6として表3に示す組成の複合粉体13〜19を調製した。製法は実施例1又は2の製法に準じた。また、その評価内容として複合粉体のしっとり感、のびの滑らかさ、撥水性について、良好を○、やや良好を△、不良を×として表3に示す。 Next, in order to determine an appropriate content of the α-tocopherol phosphate ester salt in the composite powder, composite powders 13 to 19 having the compositions shown in Table 3 as Example 6 were prepared. The production method conformed to the production method of Example 1 or 2. In addition, as evaluation contents, Table 3 shows the feeling of moistness, smoothness of smoothness, and water repellency, with “Good” as “good”, “Slightly good” as Δ, and “Poor” as bad.
従って、表3の結果から、複合粉体中のα−トコフェロールリン酸エステル塩の含有量は、0.5重量%以上でα−トコフェロールリン酸エステル塩特有のしっとり感が得られることがわかるが、含有量を過剰に増やすと、約15重量%あたりから滑らかさが失われていく傾向がある。よって、複合粉体中のα−トコフェロールリン酸エステル塩の含有量としては、0.5〜15重量%であり、しっとり感、滑らかさ、さらには撥水性まで加味すると、2〜10重量%がより好ましいことがわかる。 Therefore, from the results of Table 3, it can be seen that when the content of the α-tocopherol phosphate salt in the composite powder is 0.5% by weight or more, a moist feeling peculiar to the α-tocopherol phosphate salt can be obtained. When the content is excessively increased, the smoothness tends to be lost from about 15% by weight. Therefore, the content of the α-tocopherol phosphate ester salt in the composite powder is 0.5 to 15% by weight, and 2 to 10% by weight when moist feeling, smoothness, and even water repellency are added. It turns out that it is more preferable.
下記製法と処方にてパウダーファンデーションを調製した。
[製法]
下記処方の成分1〜8の各粉体を混合、粉砕する。その後、成分9〜12を混合して、粉砕まで行った粉体の混合物に添加し混合した後、再び粉砕し、ふるいを通した。これを金皿に圧縮成型してパウダーファンデーションを得た。
[パウダーファンデーション処方]
原料名 重量%
1 実施例1の複合粉体 10.0
2 シリコーン処理タルク 24.5
3 シリコーン処理マイカ 10.0
4 シリコーン処理セリサイト 30.0
5 シリコーン処理酸化チタン 10.0
6 シリコーン処理ベンガラ 2.0
7 シリコーン処理黄酸化鉄 3.0
8 シリコーン処理黒酸化鉄 0.1
9 スクワラン 4.0
10 ジメチルポリシロキサン 6.0
11 防腐剤 0.2
12 香料 0.2
A powder foundation was prepared by the following production method and prescription.
[Production method]
Each powder of the components 1-8 of the following prescription is mixed and pulverized. Thereafter, components 9 to 12 were mixed, added to the powder mixture which had been subjected to pulverization, mixed, then pulverized again and passed through a sieve. This was compression molded into a metal pan to obtain a powder foundation.
[Powder foundation prescription]
Raw material name Weight%
1 Composite powder of Example 1 10.0
2 Silicone-treated talc 24.5
3 Silicone-treated mica 10.0
4 Silicone-treated sericite 30.0
5 Silicone-treated titanium oxide 10.0
6 Silicone-treated Bengala 2.0
7 Silicone-treated yellow iron oxide 3.0
8 Silicone-treated black iron oxide 0.1
9 Squalane 4.0
10 Dimethylpolysiloxane 6.0
11 Preservative 0.2
12 Fragrance 0.2
[比較例5]
下記製法と処方にてパウダーファンデーションを調製した。
[製法]
実施例7の処方の成分1を、複合粉体の2つの成分である9.0重量%のセリサイト単品と1.0重量%のdl−α−トコフェロールリン酸エステルナトリウム塩単品を複合化しないで配合し、実施例7と同じ製法にて、パウダーファンデーションを得た。
[Comparative Example 5]
A powder foundation was prepared by the following production method and prescription.
[Production method]
Component 1 of the formulation of Example 7 is not combined with two components of the composite powder, 9.0% by weight of sericite and 1.0% by weight of dl-α-tocopherol phosphate sodium salt. And a powder foundation was obtained by the same production method as in Example 7.
[比較例6]
下記製法と処方にてパウダーファンデーションを調製した。
[製法]
実施例7の処方の成分1を、セリサイトに代替し、実施例7と同じ製法にて、パウダーファンデーションを得た。
[Comparative Example 6]
A powder foundation was prepared by the following production method and prescription.
[Production method]
Component 1 in the formulation of Example 7 was replaced with sericite, and a powder foundation was obtained by the same production method as in Example 7.
実施例7、比較例5及び6のパウダーファンデーションについて、本発明の複合粉体を実際にパウダーファンデーションに配合し、複合粉体化されることによって、凝集せず固まらなくなり、使用性が改善されることを確認するため、下記の試験を行った。
肌への付着、密着感:10人の専門パネラーにより官能評価を行い、下記基準で確認した。
○:8人以上が良好と評価
△:4人〜7人が良好と評価
×:3人以下が良好と評価
とれ及びケーキング:パウダーファンデーションをパフでとり続け、パウダーファンデーションの表面状態ととれ量の変化について、下記基準で確認した。
○:表面に凝集物がなく、とれ量も適度で変化しない
△:表面に凝集物は生じるが、とれ量は適度で変化しない
×:表面に凝集物が生じるともに、次第にとれ量が少なくなり、ケーキングする
For the powder foundations of Example 7 and Comparative Examples 5 and 6, the composite powder of the present invention was actually blended into the powder foundation to form a composite powder. In order to confirm this, the following test was conducted.
Attachment to skin and feeling of adhesion: Sensory evaluation was conducted by 10 professional panelists, and the following criteria were confirmed.
○: Evaluated as 8 or more good △: Evaluated as 4 to 7 as good ×: Evaluated as 3 or less as good and caking: Continued taking the powder foundation with a puff, and the surface condition and amount of the powder foundation The change was confirmed by the following criteria.
○: There is no aggregate on the surface, and the amount of removal is moderate and does not change. Δ: The aggregate is generated on the surface, but the amount of separation is moderate and does not change. X: The aggregate is formed on the surface, and the amount of separation gradually decreases. To cake
実施例7、比較例5及び6のパウダーファンデーションについて、試験を行った結果を表4に示す。 Table 4 shows the results of testing the powder foundations of Example 7 and Comparative Examples 5 and 6.
表4の結果から、本発明の複合粉体を配合した実施例7のパウダーファンデーションは、肌への付着、密着が優れ、さらに、パウダーファンデーションの表面に凝集物の発生やケーキングもなく、とれ量も適量であることがわかる。また、実施例7のパウダーファンデーションは、−5℃、5℃、20℃、40℃に保存し、一週間毎に4週間続けて、とれの試験を行っても、凝集物やケーキングの発生は見られなかった。一方、α−トコフェロールリン酸エステル塩を複合化せずに直接添加した比較例5のファンデーションは表面に凝集物が生じ、次第にとれ量が少なくなり、ケーキングした。また、α−トコフェロールリン酸エステル塩がない比較例6のファンデーションは肌への付着、密着が物足りないことがわかる。 From the results shown in Table 4, the powder foundation of Example 7 blended with the composite powder of the present invention has excellent adhesion and adhesion to the skin, and further, there is no agglomeration or caking on the surface of the powder foundation. Is also found to be an appropriate amount. In addition, the powder foundation of Example 7 was stored at −5 ° C., 5 ° C., 20 ° C., and 40 ° C., and the occurrence of agglomerates and caking did not occur even if the test was performed continuously for 4 weeks every week. I couldn't see it. On the other hand, the foundation of Comparative Example 5 to which α-tocopherol phosphate ester salt was directly added without being complexed formed aggregates on the surface, and the amount of flakes gradually decreased, resulting in caking. Moreover, it turns out that the foundation of the comparative example 6 which does not have (alpha) -tocopherol phosphate ester salt is unsatisfactory in adhesion and adhesion | attachment to skin.
化粧料全量中のα−トコフェロールリン酸エステル塩の適切な含有量を決めるため、実施例8として表5に示す組成の処方例1〜4を調製した。製法は実施例7と同様である。 In order to determine an appropriate content of the α-tocopherol phosphate ester salt in the total amount of the cosmetic, formulation examples 1 to 4 having the compositions shown in Table 5 as Example 8 were prepared. The production method is the same as in Example 7.
得られたパウダーファンデーションに対し、実施例7と同様に評価を行い、表5に結果を示す。 The obtained powder foundation was evaluated in the same manner as in Example 7, and the results are shown in Table 5.
従って、表5の処方による本発明の複合粉体を用いるパウダーファンデーションの結果から、本発明の複合粉体を用いるパウダーファンデーション全量中のα−トコフェロールリン酸エステル塩の含有量は0.01重量%を下回ると付着、密着性がやや物足りなくなり、5重量%を越えるとベースのとれがやや不十分になることがわかる。 Therefore, from the results of the powder foundation using the composite powder of the present invention according to the formulation of Table 5, the content of α-tocopherol phosphate ester salt in the total amount of the powder foundation using the composite powder of the present invention is 0.01% by weight. It is understood that adhesion and adhesion are somewhat unsatisfactory when the amount is less than 5, and the base is slightly insufficient when it exceeds 5% by weight.
さらに、α−トコフェロールリン酸エステル塩を複合化せずにファンデーションに直接配合した場合の、α−トコフェロールリン酸エステル塩の含有量に対する、ベース表面の凝集物の発生又はケーキングの発生の状況を調べるために、表6に示す比較例7〜10を、比較例5と同様の製法で調製した。 Furthermore, when the α-tocopherol phosphate salt is blended directly into the foundation without being complexed, the state of occurrence of agglomeration or caking on the base surface relative to the content of the α-tocopherol phosphate salt is examined. Therefore, Comparative Examples 7 to 10 shown in Table 6 were prepared by the same production method as Comparative Example 5.
調製した比較例7〜10を金皿に圧縮成型した状態で、−5℃、5℃、20℃、40℃の各温度に保存し、一週間毎に室温下でパフによるとれ試験を行い、経時的な使用性の変化を評価した。その結果、4週間後の時点で、比較例7は凝集物やケーキングの発生は見られなかったのに対し、ファンデーション全量中のα−トコフェロールリン酸エステル塩の含有量が0.01重量%以上である比較例8〜10は、特に、−5℃、5℃の低温保存のものが結露等により水分がしみ込みやすく、凝集物の発生やケーキングが観察された。従って、α−トコフェロールリン酸エステル塩を複合化せずに直接、ファンデーションに配合した場合、その含有量が0.01重量%以上になると、ベース表面の凝集物やケーキングが発生することが確認された。 In a state where the prepared Comparative Examples 7 to 10 were compression-molded in a metal pan, the samples were stored at −5 ° C., 5 ° C., 20 ° C., and 40 ° C., and a leak test was performed with a puff at room temperature every week. Changes in usability over time were evaluated. As a result, at the time point after 4 weeks, Comparative Example 7 showed no occurrence of aggregates or caking, whereas the content of α-tocopherol phosphate ester salt in the total amount of the foundation was 0.01% by weight or more. In Comparative Examples 8 to 10, in particular, those stored at a low temperature of −5 ° C. and 5 ° C. were likely to infiltrate moisture due to dew condensation or the like, and generation of aggregates and caking were observed. Therefore, when the α-tocopherol phosphate ester salt is blended directly into the foundation without being complexed, it is confirmed that aggregates and caking on the base surface occur when the content is 0.01% by weight or more. It was.
下記製法と処方にてフェイスパウダーを調製した。
[製法]
下記処方の成分1〜10の各粉体を混合、粉砕する。その後、成分11〜13を混合して、粉砕まで行った粉体の混合物に添加し混合した後、再び粉砕し、ふるいを通した。これを容器に充填してフェイスパウダーを得た。
[フェイスパウダー処方]
原料名 (重量%)
1 実施例3の複合粉体 4.00
2 シリコーン処理タルク 69.53
3 シリコーン処理セリサイト 15.00
4 シリコーン処理酸化チタン 0.10
5 シリコーン処理ベンガラ 0.05
6 シリコーン処理黄酸化鉄 0.06
7 シリコーン処理黒酸化鉄 0.01
8 雲母チタン 3.00
9 球状無水ケイ酸 5.00
10 防腐剤 0.20
11 スクワラン 1.00
12 ジメチルポリシロキサン 2.00
13 香料 0.05
Face powder was prepared by the following production method and prescription.
[Production method]
Each powder of the components 1-10 of the following prescription is mixed and pulverized. Thereafter, the components 11 to 13 were mixed, added to the powder mixture obtained until pulverization, mixed, then pulverized again and passed through a sieve. This was filled in a container to obtain a face powder.
[Face powder formula]
Raw material name (wt%)
1 Composite powder of Example 3 4.00
2 Silicone-treated talc 69.53
3 Silicone-treated sericite 15.00
4 Silicone-treated titanium oxide 0.10
5 Silicone-treated bengara 0.05
6 Silicone-treated yellow iron oxide 0.06
7 Silicone-treated black iron oxide 0.01
8 Titanium mica 3.00
9 Spherical silica 5.00
10 Preservative 0.20
11 Squalane 1.00
12 Dimethylpolysiloxane 2.00
13 Fragrance 0.05
上記処方で得られたフェイスパウダーの実施例9は、実施例7と同様に肌への付着性が優れ、凝集物のないフェイスパウダーであった。従って、本発明である実施例3の複合粉体の効果であると考えられる。 Example 9 of the face powder obtained by the above formulation was a face powder having excellent adhesion to the skin and having no aggregates as in Example 7. Therefore, it is considered that this is the effect of the composite powder of Example 3 according to the present invention.
下記製法と処方にてアイシャドウを調製した。
[製法]
下記処方の成分1〜7の各粉体を混合、粉砕した。その後、成分8〜10を混合して、粉砕まで行った粉体の混合物に添加し混合した後、再び粉砕した。これに成分11を加え、混合した後、ふるいを通した。これを金皿に圧縮成型してアイシャドウを得た。
[アイシャドウ処方]
原料名 (重量%)
1 実施例2の複合粉体 5.00
2 セリサイト 47.75
3 グンジョウ 2.00
4 ポリアクリル酸アルキル 5.00
5 窒化ホウ素 5.00
6 球状無水ケイ酸 5.00
7 防腐剤 0.20
8 スクワラン 5.00
9 メチルフェニルポリシロキサン 5.00
10 香料 0.05
11 雲母チタン 20.00
An eye shadow was prepared by the following production method and formulation.
[Production method]
Each powder of the components 1-7 of the following prescription was mixed and pulverized. Thereafter, components 8 to 10 were mixed, added to the mixture of powders until pulverization, mixed, and then pulverized again. Ingredient 11 was added to this, mixed and passed through a sieve. This was compression molded into a metal pan to obtain an eye shadow.
[Eyeshadow prescription]
Raw material name (wt%)
1 Composite powder of Example 2 5.00
2 Sericite 47.75
3 Gunjo 2.00
4 Alkyl polyacrylate 5.00
5 Boron nitride 5.00
6 Spherical silica 5.00
7 Preservative 0.20
8 Squalane 5.00
9 Methylphenylpolysiloxane 5.00
10 Fragrance 0.05
11 Mica titanium 20.00
上記処方で得られたアイシャドウの実施例10は、実施例7と同様に肌への付着性が優れ、ケーキングのないアイシャドウであった。従って、本発明である実施例2の複合粉体の効果であると考えられる。 Example 10 of the eye shadow obtained by the above formulation was an eye shadow having excellent adhesion to the skin as in Example 7 and having no caking. Therefore, this is considered to be the effect of the composite powder of Example 2 according to the present invention.
下記製法と処方にて口紅を調製した。
[製法]
下記処方の成分8〜10をローラーミルにて分散させる。その後、成分1〜7を加温融解して、成分8〜10の混合物と成分11〜13を加え、よく混合する。ろ過し、高温で型に流し込み、冷却して成型したものを容器に装填して口紅を得た。
[口紅処方]
原料名 (重量%)
1 セレシン 10.00
2 マイクロクリスタリンワックス 2.00
3 カルナウバロウ 1.00
4 合成炭化水素ワックス 2.00
5 ダイマー酸イソプロピル 15.00
6 トリ(カプリル・カプリン酸)グリセリン 33.95
7 ジペンタエリトリット脂肪酸エステル 3.50
8 トリイソステアリン酸ポリグリセリル 12.00
9 着色料 6.50
10 実施例4の複合粉体 1.00
11 合成金雲母 9.00
12 球状無水ケイ酸 4.00
13 香料 0.05
Lipstick was prepared by the following production method and prescription.
[Production method]
Ingredients 8-10 of the following formulation are dispersed with a roller mill. Then, components 1-7 are heated and melted, and a mixture of components 8-10 and components 11-13 are added and mixed well. The product was filtered, poured into a mold at high temperature, cooled and molded into a container, and a lipstick was obtained.
[Lipstick prescription]
Raw material name (wt%)
1 Ceresin 10.00
2 Microcrystalline wax 2.00
3 Carnauba 1.00
4 Synthetic hydrocarbon wax 2.00
5 Isopropyl dimer acid 15.00
6 Tri (capryl / capric acid) glycerin 33.95
7 Dipentaerythritol fatty acid ester 3.50
8 Polyglyceryl triisostearate 12.00
9 Coloring 6.50
10 Composite powder of Example 4 1.00
11 Synthetic phlogopite 9.00
12 Spherical Silicic Acid 4.00
13 Fragrance 0.05
上記処方で得られた口紅の実施例11は、唇に対する付着性が優れる口紅であった。また、吸湿や口唇まわりの水分による凝集物の発生がなく、ざらつきのない滑らかな使用感のものであった。従って、本発明である実施例4の複合粉体の効果であると考えられる。 Example 11 of the lipstick obtained by the above formulation was a lipstick with excellent adhesion to the lips. Moreover, there was no generation of agglomerates due to moisture absorption or moisture around the lips, and there was a smooth feeling of use with no roughness. Therefore, it is considered that this is the effect of the composite powder of Example 4 which is the present invention.
下記製法と処方にて油中水型乳化ファンデーションを調製した。
[製法]
下記処方の成分1〜7を加熱混合し、成分8〜16を均一に混合したものを添加して均一に分散する。その後、成分17〜20を加熱混合したものを加えて乳化する。充填は、得られた乳化物を容器に流して行い、冷却固化して油中水型乳化型ファンデーションを得た。
[油中水型乳化型ファンデーション処方]
原料名 (重量%)
1 キャンデリラワックス 4.00
2 マイクロクリスタリンワックス 3.00
3 パラフィンワックス 7.00
4 デカメチルシクロペンタシロキサン 26.00
5 トリメチルシロキシケイ酸 10.00
6 メチルフェニルポリシロキサン 1.00
7 (アクリル酸アルキル/ジメチコン)コポリマー 2.00
8 シリコーン処理酸化チタン 16.00
9 シリコーン処理黄酸化鉄 1.70
10 シリコーン処理ベンガラ 0.50
11 シリコーン処理黒酸化鉄 0.20
12 ポリアクリル酸アルキル 2.00
13 ナイロン末 2.00
14 シリコーン処理タルク 2.50
15 無水ケイ酸 3.00
16 実施例3の複合粉体 4.00
17 防腐剤 0.10
18 1,3−ブチレングリコール 3.00
19 グリセリン 3.00
20 精製水 9.00
A water-in-oil emulsified foundation was prepared by the following production method and formulation.
[Production method]
Components 1 to 7 having the following formulation are mixed by heating, and the components 8 to 16 mixed uniformly are added and dispersed uniformly. Thereafter, the components 17 to 20 mixed with heating are added and emulsified. The obtained emulsion was poured into a container and cooled and solidified to obtain a water-in-oil emulsion foundation.
[Water-in-oil emulsified foundation formulation]
Raw material name (wt%)
1 Candelilla wax 4.00
2 Microcrystalline wax 3.00
3 Paraffin wax 7.00
4 Decamethylcyclopentasiloxane 26.00
5 Trimethylsiloxysilicic acid 10.00
6 Methylphenylpolysiloxane 1.00
7 (alkyl acrylate / dimethicone) copolymer 2.00
8 Silicone-treated titanium oxide 16.00
9 Silicone-treated yellow iron oxide 1.70
10 Silicone-treated Bengala 0.50
11 Silicone-treated black iron oxide 0.20
12 Alkyl polyacrylate 2.00
13 Nylon powder 2.00
14 Silicone-treated talc 2.50
15 Silicic anhydride 3.00
16 Composite powder of Example 3 4.00
17 Preservative 0.10
18 1,3-butylene glycol 3.00
19 Glycerin 3.00
20 Purified water 9.00
上記処方で得られた油中水型乳化型ファンデーションの実施例12は、実施例7と同様に肌への付着性が優れ、凝集物のない滑らかな使用感の油中水型乳化型ファンデーションであった。従って、本発明である実施例3の複合粉体の効果であると考えられる。 Example 12 of the water-in-oil emulsified foundation obtained by the above formulation is a water-in-oil emulsified foundation having excellent adhesion to the skin and free of agglomerates as in Example 7. there were. Therefore, it is considered that this is the effect of the composite powder of Example 3 according to the present invention.
複合粉体の保湿効果として、複合粉体を配合したパウダーファンデーションの塗膜による水分蒸散量の抑制効果を評価した。用いた各パウダーファンデーションの処方は下記表7の処方例5〜8の組成であり、製法は実施例7に準じた。 As a moisturizing effect of the composite powder, the effect of suppressing moisture transpiration by the coating film of the powder foundation containing the composite powder was evaluated. The prescription of each powder foundation used was the composition of Prescription Examples 5 to 8 in Table 7 below, and the production method was in accordance with Example 7.
水分蒸散の抑制効果の評価は下記のようにして行った。
1.各パウダーファンデーションをアドバンテック社のNo.131のろ紙にパフにて均一に塗布し、2cm四方の正方形に切り分けた。このうち、塗布前後の重量差から、塗布量が4cm2あたり2.5〜5.0mgであるものを選び出し試料とした。
2.上記1で準備した試料の塗布面の裏側にマイクロシリンジを用いて1マイクロリットルの精製水を染み込ませ、塗布面を表にしてガラス板上に1分間放置した。
3.塗布面から蒸散する水分量を、下記に示す経表皮水分喪失量測定(TEWL)に用いられる密封セル法により算出した。
4.上記2で準備した試料に密封セルを載せ、一定の乾燥空気を循環させて、エバポリメーター(スキノス社製AS−TW2型)を用いて水蒸気圧を検知した。水蒸気圧をチャート紙に検出し、一定(恒量)となる時点を終点とした(図1、測定気温18〜23℃、湿度40〜50%)。
5.チャート紙の曲線グラフについて、測定開始2分後を始点とし、終点までの面積を蒸散量とした。この値から同測定時間における恒量の蒸散量分を除いた値を蒸散量T1とした。つまり、蒸散量T1は水蒸気圧の曲線グラフ、2分の時間軸、終点の水蒸気圧軸に囲まれた面積である。なお、この蒸散量T1である面積は、一度、同じ種類の紙でチャート紙の複写をとり、蒸散量範囲を切り抜いた後、重量測定することで見積もった(測定を5回繰り返し、最大値と最小値を示した2回を除いた3回の平均値)。
6.さらに、パウダーファンデーションを塗布することによる効果を見積もるため、同様な方法にて求めたパウダーファンデーション未塗布(ろ紙のみ)の蒸散量T0を差し引いて、蒸散量を補正した(蒸散量T=T1−T0)。
7.パウダーファンデーション塗布による水分蒸散の抑制効果は、パウダーファンデーションの塗膜があることによって長い時間にわたり多くの水を蒸散するので、求められた蒸散量Tの逆数、すなわち、抑制パラメーター(1/T)によって評価した。
8.複合粉体配合による水の蒸散抑制効果の評価は、表7の各処方例のパウダーファンデーションの1/T値が、各パウダーファンデーションの複合粉体の核粉体のみに置き換えて測定した1/T値の何倍であるかを求めて行った。
Evaluation of the suppression effect of water transpiration was performed as follows.
1. Each powder foundation is a No. of Advantech. It was uniformly applied to 131 filter papers with a puff and cut into 2 cm squares. Among these, a sample having a coating amount of 2.5 to 5.0 mg per 4 cm 2 was selected from the difference in weight before and after coating and used as a sample.
2. Using a microsyringe, 1 microliter of purified water was impregnated on the back of the coated surface of the sample prepared in 1 above, and the sample was left on the glass plate for 1 minute with the coated surface facing up.
3. The amount of water evaporated from the coated surface was calculated by the sealed cell method used for transepidermal water loss measurement (TEWL) shown below.
4). A sealed cell was placed on the sample prepared in 2 above, and constant dry air was circulated, and the water vapor pressure was detected using an evaporator (AS-TW2 model manufactured by Skinos). The water vapor pressure was detected on the chart paper, and the time point at which the water vapor pressure became constant (constant weight) was taken as the end point (FIG. 1, measured temperature 18-23 ° C., humidity 40-50%).
5. For the curve graph of the chart paper, the starting point was 2 minutes after the start of measurement, and the area to the end point was defined as the amount of transpiration. A value obtained by removing a constant amount of transpiration during this measurement time from this value was defined as transpiration amount T1. That is, the transpiration amount T1 is an area surrounded by a water vapor pressure curve graph, a time axis of 2 minutes, and a water vapor pressure axis at the end point. The area corresponding to the amount of transpiration T1 was estimated by copying the chart paper once with the same type of paper, cutting out the transpiration range, and measuring the weight (repeating the measurement five times to obtain the maximum value). 3 average values excluding 2 times showing the minimum value).
6). Furthermore, in order to estimate the effect of applying the powder foundation, the transpiration amount was corrected by subtracting the transpiration amount T0 of the powder foundation uncoated (filter paper only) obtained by the same method (transpiration amount T = T1-T0). ).
7). The suppression effect of moisture transpiration by the application of powder foundation is that a lot of water evaporates for a long time due to the presence of the coating film of the powder foundation. evaluated.
8). The evaluation of the water transpiration control effect by the composite powder blending was measured by replacing the 1 / T value of the powder foundation of each formulation example in Table 7 with only the core powder of the composite powder of each powder foundation. I asked for how many times the value.
上記のようにして求めた処方例5〜8の複合粉体配合による水の蒸散抑制効果を表8に示す。 Table 8 shows the transpiration control effect of the composite powder blends of Formulation Examples 5 to 8 determined as described above.
表8の結果より、α−トコフェロールリン酸エステル塩を2重量%以上含む複合粉体をパウダーファンデーションに1重量%以上含有させた場合、パウダーファンデーションの塗膜によって、水分の蒸散を抑制できることが明らかとなった。これにより、本願発明の複合粉体を含有するメイクアップ化粧料は、α−トコフェロールリン酸エステル塩の保湿効果で肌のうるおいを守る化粧料であることが示唆された。 From the results of Table 8, it is clear that when the composite powder containing 2% by weight or more of α-tocopherol phosphate ester salt is contained in the powder foundation by 1% by weight or more, transpiration of water can be suppressed by the coating film of the powder foundation. It became. This suggests that the makeup cosmetic containing the composite powder of the present invention is a cosmetic that protects the moisture of the skin by the moisturizing effect of α-tocopherol phosphate ester salt.
本発明の核粉体とα−トコフェロールリン酸エステル塩からなる複合粉体を配合することによって、化粧料のみならず医薬品をはじめ他の産業における製品にも応用でき、品質の改善が期待できる。 By blending the composite powder composed of the core powder of the present invention and α-tocopherol phosphate ester salt, it can be applied not only to cosmetics but also to products in other industries including pharmaceuticals, and improvement in quality can be expected.
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006062696A JP4781855B2 (en) | 2006-03-08 | 2006-03-08 | Composite powder and makeup cosmetic containing the composite powder |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006062696A JP4781855B2 (en) | 2006-03-08 | 2006-03-08 | Composite powder and makeup cosmetic containing the composite powder |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007238497A JP2007238497A (en) | 2007-09-20 |
JP4781855B2 true JP4781855B2 (en) | 2011-09-28 |
Family
ID=38584381
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006062696A Active JP4781855B2 (en) | 2006-03-08 | 2006-03-08 | Composite powder and makeup cosmetic containing the composite powder |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4781855B2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5662794B2 (en) * | 2010-12-21 | 2015-02-04 | 株式会社ファンケル | Water-in-oil emulsion composition |
JP2017197559A (en) | 2017-06-09 | 2017-11-02 | 味の素株式会社 | Composite powders and makeup cosmetics |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0617317B2 (en) * | 1985-04-12 | 1994-03-09 | フロイント産業株式会社 | Free-flowing powder composition |
FR2657526B1 (en) * | 1990-01-31 | 1994-10-28 | Lvmh Rech | USE OF AN ALPHA-TOCOPHEROL PHOSPHATE, OR ONE OF ITS DERIVATIVES, FOR THE PREPARATION OF COSMETIC, DERMATOLOGICAL, OR PHARMACEUTICAL COMPOSITIONS; COMPOSITIONS THUS OBTAINED. |
JP3035742B2 (en) * | 1990-11-30 | 2000-04-24 | 昭和電工株式会社 | Cosmetics |
JPH09309813A (en) * | 1996-05-22 | 1997-12-02 | Nonogawa Shoji Kk | Preparation for external use for skin |
JP3746130B2 (en) * | 1997-01-22 | 2006-02-15 | 竹本油脂株式会社 | Synthetic fiber spinning oil |
JP4200593B2 (en) * | 1999-06-22 | 2008-12-24 | 昭和電工株式会社 | Crystalline L-ascorbic acid-2-phosphate sodium salt and process for producing the same |
JP2003183129A (en) * | 2001-12-20 | 2003-07-03 | Nonogawa Shoji Kk | Makeup cosmetic |
JP2004026817A (en) * | 2002-05-09 | 2004-01-29 | Showa Denko Kk | Skin care preparation for bleaching |
-
2006
- 2006-03-08 JP JP2006062696A patent/JP4781855B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2007238497A (en) | 2007-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5174789B2 (en) | O / W emulsified cosmetic | |
JP3107891B2 (en) | Water-containing powder cosmetics | |
KR20020060164A (en) | Water-containing powder composition, process for producing the same, and cosmetic preparation containing the powder composition | |
WO2006083387A1 (en) | Personal care compositions comprising coated/treated metal silicate absorbent particles | |
JP3219886B2 (en) | Powder cosmetics | |
US7718184B2 (en) | Hydrophobically coated/treated metal silicate absorbent particles and personal care compositions thereof | |
JPH10158115A (en) | Cosmetic | |
EP1402875B1 (en) | Powdery composition | |
JP3812733B2 (en) | Powdered composition | |
JP4781855B2 (en) | Composite powder and makeup cosmetic containing the composite powder | |
JP6474744B2 (en) | Water-in-oil emulsified cosmetic | |
JP4880078B1 (en) | Powder cosmetics | |
JP2004300057A (en) | Water-containing powder cosmetic | |
CN111526858A (en) | Cosmetic composition for blurring surface blemishes of skin | |
JPH07173044A (en) | Cosmetic | |
JP6644416B2 (en) | Composition for suppressing body odor | |
JP3511415B2 (en) | Composite powder and cosmetics | |
JP2014166962A (en) | Hydrous powder cosmetic | |
JP3448751B2 (en) | Ultraviolet shielding powder and cosmetics containing the same | |
JPH05285370A (en) | Water and oil repellent powder and cosmetic containing the same | |
JPH1192333A (en) | Oil-in-water type solid cosmetic | |
JP2022091422A (en) | Powder cosmetic for improving makeup durability | |
JPH0539209A (en) | Complex cosmetic powder and cosmetic containing the same powder | |
JPH09510474A (en) | Powder cosmetic composition | |
JP6652241B2 (en) | Solid powder cosmetics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090121 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101130 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101225 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110705 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110706 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140715 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4781855 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |